Landmark step in malaria vaccines as first trial meets WHO target
Issued on:
25/04/2021 - 09:56 Malaria killed at least four times as many more people in Africa last year as Covid did, Professor Adrian Hill said Olympia DE MAISMONT AFP/File 4 min As the world marks World Malaria Day, a new vaccine has proven 77 percent effective in trials on infants, according to British researchers, in what could prove to be a potential game-changer against the deadly mosquito-borne disease. Advertising Read more
In a clinical trial in Burkina Faso, the Matrix-M vaccine developed by the University of Oxford s Jenner Institute was found to be 77 percent effective after 450 infants inoculated in 2019 were followed up for a year, the Oxford researchers said in a statement.
Vaccine against malaria could be first real breakthrough hotair.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from hotair.com Daily Mail and Mail on Sunday newspapers.
Share
Community health workers distribute medicine aimed at preventing seasonal malaria in Burkina Faso. A recent successful clinical trial has raised hopes for a vaccine against the disease. LYMPIA DE MAISMONT/AFP via Getty Images
Malaria vaccine has striking early success after decades of disappointment
Apr. 23, 2021 , 8:25 PM
After decades of disappointing results, recent findings have revived hopes for an effective vaccine against malaria, which kills some 400,000 people every year, most of them children. An experimental vaccine that targets the most dangerous form of the malaria parasite was found to have an efficacy of 74% to 77% after 1 year in children from West Africa.
New Vaccine Highly Effective Against Malaria: Researchers
Researchers at the University of Oxford’s Jenner Institute have made a major breakthrough by developing a malaria vaccine that has proven to be 77 percent effective in early trials.
Malaria claims the lives of over 400,000 people annually. Many malaria vaccines have undergone trials over a number of years, but this is the first one that has met the required target.
According to the researchers, this vaccine can have a huge impact on public health.
ALSO READ
For the trial phase, the vaccine was administered to 450 children in Burkina Faso, and it was observed to be safe and displayed ‘high-level efficacy over a follow-up period of 12 months.